A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/136 (2006.01) A61K 9/00 (2006.01) A61K 9/06 (2006.01) A61K 47/32 (2006.01) A61P 17/00 (2006.01) A61P 17/10 (2006.01)
Patent
CA 2704859
The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also discloses the treatment of dermatological conditions in G6PD-def icient patients with the composition, while avoiding adverse hematologic effects.
Cette invention concerne un système d'excipient pharmaceutique comprenant une composition dermatologique sous forme de gel aqueux semi-solide, caractérisé en ce que le dapsone est dissous dans le gel de façon à pouvoir traverser la couche cornée de l'épiderme, et en ce que la composition contient aussi du dapsone à l'état microparticulaire qui ne traverse pas facilement la couche cornée de l'épiderme. L'invention décrit aussi le traitement d'affections dermatologiques chez des patients déficients en G6PD avec la composition, tout en évitant les effets indésirables hématologiques.
Allergan Inc.
Gowling Lafleur Henderson Llp
LandOfFree
Topical treatment with dapsone in g6pd-deficient patients does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical treatment with dapsone in g6pd-deficient patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical treatment with dapsone in g6pd-deficient patients will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2069966